In the Chemotherapy, Herceptin and Lapatinib in Operable Breast cancer (CHER-LOB) study, similar pCR rates after neoadjuvant paclitaxel for 12 weeks followed by fluorouracil, epirubicin and cyclophosphamide for four courses every 3 weeks plus HER2-targeted therapy were seen in patients with PIK3CA-WT and PIK3CA-mutated breast cancers (33.3% vs. 22.7%; p = 0.323) [34]. Here, ERBB2 is linked to breast cancer.